Ronald C. Petersen, M.D., Ph.D.

The purpose of this study is the validation of biomarker measures and to nform clinical trial design.

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

The goal of this project is to assess the validity and efficacy of online methods to predict and monitor cognitive and functional decline in elders with normal cognition (CN), subjective memory complaints (SMC), and mild cognitive impairment (MCI) using electronic versions of the Clinical Dementia Rating Scale (CDR) and the Financial Capacity Instrument-Short Form (FCI-SF). We will validate the e-instruments by implementing them within the Brain Health Registry (BHR, CHR #12-09628), and comparing online data obtained unsupervised at home with online data obtained while supervised in research clinics, over the telephone, or by video technology from participants followed longitudinally for 4 years and across 4 sites. In addition to the newly-developed electronic CDR (eCDR) and electronic FCI (eFCI), we will use BHR data, including the Cogstate Brief Battery and additional self-report questionnaires, to determine whether these electronic instruments can both measure and predict cognitive and functional decline. We also intend to determine the ability of electronic instruments to predict ß-amyloid (Aß) PET positivity. The development and validation of scalable, accessible screening tools, such as online electronic instruments, will likely lead to improved methods that can be used in clinical trials and multiple healthcare settings to identify people at risk for and undergoing cognitive and functional decline and Alzheimer’s disease (AD), ultimately leading to prevention of AD and improved healthcare for neurodegenerative disorders.

The purpose of this study is to evaluate and compare the clinical usefulness of plasma and MRI-based MarkVCID biomarkers in relation to age, sex, systemic vascular health, race, ethnicity and cognition.

This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia.

The purpose of this study is to learn more about using a computerized test in your home to study how memory changes with age, mild memory and thinking problems and Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.

This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.